Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
08:56am, Thursday, 09'th Jan 2025
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?
12:57pm, Tuesday, 07'th Jan 2025
Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
08:59am, Tuesday, 31'st Dec 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
01:41pm, Tuesday, 24'th Dec 2024
GKOS announces New Drug Application submission for its Epioxa to the FDA.
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
07:00am, Monday, 23'rd Dec 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos: Still Bullish, But Embedded Expectations Are Now High
07:04am, Saturday, 21'st Dec 2024
Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sa
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
03:16am, Thursday, 12'th Dec 2024
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
09:36am, Wednesday, 11'th Dec 2024
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
5 Medical Device Stocks That Survived the 2024 Market Volatility
08:55am, Wednesday, 11'th Dec 2024
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were s
Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?
09:50am, Thursday, 21'st Nov 2024
GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Glaukos Announces Participation in Upcoming Investor Conferences
07:00am, Friday, 08'th Nov 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
12:31pm, Tuesday, 05'th Nov 2024
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
12:21pm, Tuesday, 05'th Nov 2024
Glaukos Corp GKOS reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million.
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
11:01am, Tuesday, 05'th Nov 2024
Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
